This 2015 study from the Study of Women’s Health Across the Nation (SWAN) evaluated the duration of frequent vasomotor symptoms (VMS), such as hot flashes and night sweats, in 1,449 women. The median duration of frequent VMS was 7.4 years overall, with symptoms persisting for a median of 4.5 years
This 2022 position statement by the North American Menopause Society (NAMS) updates the 2017 guidance on hormone therapy (HT) for menopausal individuals. HT remains the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause and is shown to prevent bone loss and fractures. The benefits and risks of
This observational study examined the relationship between serum estrogen levels after hormone replacement therapy (HRT) and body mass index (BMI) in postmenopausal and bilaterally ovariectomized women. It found that daily HRT administration led to a significant positive correlation between serum estradiol levels and BMI (P < 0.05 and P <
This randomized controlled trial examined the effects of escitalopram, an SSRI, on sexual function in nondepressed midlife women experiencing vasomotor symptoms (VMS). Over an 8-week period, escitalopram did not significantly impact overall sexual function compared to placebo, though small reductions in lubrication (P=0.02) and a marginally nonsignificant decrease in orgasm
This randomized controlled trial investigated the effects of six-month oral dehydroepiandrosterone (DHEA) supplementation (50 mg/day) on hormonal levels, adrenal function, and menopausal symptoms in early and late postmenopausal women. The study found significant increases in circulating androgens, estrogens, and beta-endorphins, along with decreased cortisol and gonadotropins. Participants experienced improved menopausal
The Italian Association of Sleep Medicine (AIMS) published a position statement and guideline in Maturitas (2019) on managing sleep disorders in postmenopausal women. This comprehensive review addresses sleep disturbances such as insomnia, circadian rhythm disorders, obstructive sleep apnea (OSA), restless legs syndrome (RLS), and the impact of vasomotor symptoms (VMS)
This review discusses the management of menopausal symptoms, focusing on the effectiveness of hormonal and non-hormonal treatments. It highlights that systemic estrogen therapy is the most effective treatment for managing vasomotor symptoms, providing a 75% reduction in symptoms. However, it also addresses the associated risks, including increased chances of stroke,
his cohort study examined the impact of hormone therapy (HT) and complementary alternative medicine (CAM) on the quality of life (QoL) in midlife women experiencing vasomotor and genitourinary menopause symptoms. Results showed that HT was associated with a significantly higher QoL than CAM, particularly for women with more severe symptoms.
This study investigated the effectiveness of oral micronized progesterone in alleviating vasomotor symptoms (VMS) such as hot flushes and night sweats in healthy postmenopausal women. The study, involving 133 women aged 44-62, found that those receiving 300 mg of oral micronized progesterone daily experienced significantly greater reductions in VMS compared
This review explores the physiological changes associated with natural and surgical menopause, focusing on hormonal fluctuations and their impact on women’s health. Menopause leads to significant declines in estrogen and progesterone, with testosterone also playing a role in sexual desire and overall well-being. Hormone replacement therapy (HRT) can alleviate symptoms
